Although this pathway has often been targeted in clinical trials, the majority of the CNAs and mutations in the RTK/RAS/PI-3K pathway are clonal events, as determined by fluorescence in situ hybridization (FISH) for PDGFRA amplifications (37) and mutation allele frequency of PIK3CA, suggesting these events likely arise later in tumor development. Here, PDGFRA is linked to neoplasm.